Volume 22 Issue 8
Aug.  2024
Turn off MathJax
Article Contents
DAN Gang, SUN Wei, CHEN Qinghong, HU Lina, GUO Zhengbin, ZHANG Jianhua, ZHANG Rui, LIU Yuan. Establishment and application of standard operation procedure for the entire process of lupus anticoagulant DRVVT detection[J]. Chinese Journal of General Practice, 2024, 22(8): 1390-1394. doi: 10.16766/j.cnki.issn.1674-4152.003643
Citation: DAN Gang, SUN Wei, CHEN Qinghong, HU Lina, GUO Zhengbin, ZHANG Jianhua, ZHANG Rui, LIU Yuan. Establishment and application of standard operation procedure for the entire process of lupus anticoagulant DRVVT detection[J]. Chinese Journal of General Practice, 2024, 22(8): 1390-1394. doi: 10.16766/j.cnki.issn.1674-4152.003643

Establishment and application of standard operation procedure for the entire process of lupus anticoagulant DRVVT detection

doi: 10.16766/j.cnki.issn.1674-4152.003643
Funds:

 2021YJ0191

  • Received Date: 2024-03-18
    Available Online: 2024-11-19
  •   Objective   To investigate the standardized procedure for the entire process of lupus anticoagulant (LA) detection using the dilute Russell viper venom time (DRVVT) method to ensure the accuracy of LA test results and to aid in clinical diagnosis and treatment.   Methods   This study followed relevant industry requirements, including "Management Measures for Medical Institution Laboratory Management" and "Quality Requirements for Routine Analysis of Clinical Hematology Tests WS/T 406-2012". The entire process of LA detection using the DRVVT method, including pretest, test and posttest phases stages, was standardized. A "DRVVT Method Lupus Anticoagulant Detection Manual" was created based on standard operating procedures (SOP), and test results were tracked and monitored throughout the process to ensure the accuracy of LA test results and to aid in clinical diagnosis and treatment. The study included a total of 3 595 specimens for LA testing in General Hospital of Western Theater Command PLA, from 2021 to 2023. By analyzing aspects such as the number of specimens submitted, the distribution of submitting departments and annual growth, the study examined the degree of clinical recognition of this project and the improvement in the accuracy of disease diagnosis after establishing a standardized testing process.   Results   By establishing a set of standardized operation and detection procedures, we can effectively monitor the test results, and accurately reflect the concentration of LA in patients, to provide effective support for diagnosis and treatment. With the continuous implementation of standardized procedures, the clinical recognition of relevant items has been improved, leading to a sustained increase in the number of specimens and departments submitting specimen. The number of specimens increased from 841 in 2021 to 1 460 in 2023, with a growth rate of 73.0%. In terms of departments submitting specimen, there were 16 departments in 2021 and this number reached 29 departments in 2023, with a growth rate of 81.3%. This has fully achieved the desired effect of supporting the clinic and actively interacting with the clinical department.   Conclusion   Establishing a standard process for the detection of LA can provide accurate and truthful detection results to the clinical, deepen communication with the clinical on related diseases, and play a positive role in supporting the diagnosis and treatment of related diseases.

     

  • loading
  • [1]
    胡长春, 王晓慧, 陈虹. 狼疮抗凝物检测在静脉血栓栓塞症中的应用进展[J]. 中华结核和呼吸杂志, 2022, 45(2): 218-221. doi: 10.3760/cma.j.cn112147-20210519-00339

    HU C C, WANG X H, CHEN H. Advancements in the application of lupus anticoagulant testing in venous thromboembolism[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2022, 45(2): 218-221. doi: 10.3760/cma.j.cn112147-20210519-00339
    [2]
    《中国血栓性疾病防治指南》专家委员会. 中国血栓性疾病防治指南[J]. 中华医学杂志, 2018, 98(36): 2861-2888. doi: 10.3760/cma.j.issn.0376-2491.2018.36.002

    Expert Committee of the 《Guidelines of Chinese Thromboembolic Disease Prevention and Treatment》. Guidelines of chinese thromboembolic disease prevention and treatment[J]. Chinese Medical Journal, 2018, 98(36): 2861-2888. doi: 10.3760/cma.j.issn.0376-2491.2018.36.002
    [3]
    尚红, 王毓三, 申子瑜. 全国临床检验操作规程[M]. 4版. 北京: 人民卫生出版社, 2015.

    SHANG H, WANG Y S, SHEN Z Y. National Guide to Clinical Laboratory Procedures (Version. 4)[M]. Beijing: People ' s Medical Publishing House, 2015.
    [4]
    卫生部临床检验标准专业委员会. WS/T406-2012临床血液学检验常规项目分析质量要求[S]. 北京: 2012. (2012-12-25)[2024-01-28]. http://www.nhc.gov.cn/fzs/s7852d/201301/083b633bb7bf47ba8ca6705 b687b264e.shtml.

    The Professional Committee for Clinical Laboratory Standards of the Ministry of Health. WS/T406-2012 analytical quality specifications for routine tests in clinical hematology[S]. Beijing: 2012. (2012-12-25)[2024-01-28]. http://www.nhc.gov.cn/fzs/s7852d/201301/083b633bb7bf47ba8ca6705 b687b264e.shtml.
    [5]
    谢波, 徐升强, 崔天盆. 狼疮抗凝物实验室规范化检测进展[J]. 临床检验杂志, 2016, 34(2): 144-146.

    XIE B, XU S Q, CUI T P, et al. Standardized testing progress in lupus anticoagulant laboratory[J]. Chin J Clin Lab Sci, 2016, 34(2): 144-146.
    [6]
    寿玮龄, 陈倩, 范连凯, 等. 3种稀释蝰蛇毒磷脂时间试验检测狼疮抗凝物的性能评价[J]. 临床检验杂志, 2020, 38(10): 734-737.

    SHOU W L, CHEN Q, FAN L K, et al. Performance evaluation of three diluted Russell viper venom time tests for the detection of lupus anticoagulant[J]. Chin J Clin Lab Sci, 2020, 38(10): 734-737.
    [7]
    中华人民共和国卫生部. 临床实验室检验项目参考区间的制定: WS/T402-2012[S]. 北京: 中国标准出版社, 2012.

    Ministry of Health of the People ' s Republic of China. The establishment of reference ranges for clinical laboratory test items: WS/T402-2012[S]. Beijing: Standards Press of China, 2012.
    [8]
    寿玮龄, 陈倩, 吴卫, 等. 改良蝰蛇毒磷脂时间试验和硅凝固时间试验检测狼疮抗凝物的性能验证[J]. 检验医学, 2017, 32(3): 224-228. doi: 10.3969/j.issn.1673-8640.2017.03.016

    SHOU W L, CHEN Q, WU W, et al. Performance of lupus anticoagulant assays based on diluted Russell viper venom time and silica clotting time[J]. Laboratory Medicine, 2017, 32(3): 224-228. doi: 10.3969/j.issn.1673-8640.2017.03.016
    [9]
    罗磊, 陈朴, 朱建锋, 等. Rosner指数在血浆APTT纠正试验中的应用[J]. 检验医学与临床, 2023, 20(3): 306-309. doi: 10.3969/j.issn.1672-9455.2023.03.005

    LUO L, CHEN P, ZHU J F, et al. Application of Rosner index in plasma activated partial thromboplastin time correctinttest[J]. Lab Med Clin, 2023, 20(3): 306-309. doi: 10.3969/j.issn.1672-9455.2023.03.005
    [10]
    KEELING D, MACKIE I, MOORE G W, et al. Guidelines on the investigation and management of antiphospholipid syndrome[J]. Br J Haematol, 2012, 157(1): 47-58. doi: 10.1111/j.1365-2141.2012.09037.x
    [11]
    中国研究型医院学会血栓与止血专委会. 活化部分凝血活酶时间延长混合血浆纠正试验操作流程及结果解读中国专家共识[J]. 中华检验医学杂志, 2021, 44(8): 690-697. doi: 10.3760/cma.j.cn114452-20201202-00870

    Chinese Society on Thrombosis and Hemostasis. Chinese expert consensus on operation procedure and result interpretation of APTT mixing test[J]. Chin J Lab Med, 2021, 44(8): 690-697. doi: 10.3760/cma.j.cn114452-20201202-00870
    [12]
    杨仁池, 中华医学会血液学分会血栓与止血学组, 中国血友病协作组. 凝血因子Ⅷ/Ⅸ抑制物诊断与治疗中国指南(2018年版)[J]. 中华血液学杂志, 2018, 39(10): 793-799.

    Chinese Society of Hematology Thrombosis and Hemostasis Group, China Hemophilia Collaboration Group. Comments on Chinese guidelines on the diagnosis and treatment of coagulation factor Ⅷ/Ⅸ inhibitors (version 2018)[J]. Chinese Journal of Hematology, 2018, 39(10): 793-799.
    [13]
    张金, 李程, 韩笑蓉, 等. 抗磷脂综合征相关循环系统表现[J]. 中华全科医学, 2021, 19(9): 1557-1561.

    ZHANG J, LI C, HAN X R, et al. Circulatory system manifestations of antiphospholipid antibody syndrome[J]. Chinese Journal of General Practice, 2021, 19(9): 1557-1561.
    [14]
    KOLITZ T, SHIBER S, SHARABI I, et al. Cardiac manifestations of antiphospholipid syndrome with focus on its primary form[J]. Front Immunol, 2019, 10: 941. doi: 10.3389/fimmu.2019.00941
    [15]
    邵利江, 宗建平, 陈先汉, 等. 结缔组织病合并肺栓塞13例临床分析[J]. 中华全科医学, 2016, 14(5): 712-714, 822. doi: 10.16766/j.cnki.issn.1674-4152.2016.05.005

    SHAO L J, ZONG J P, CHEN X H, et al. Clinical characteristics of pulmonary embolism in patients with connective tissue disease: an analysis of 13 cases[J]. Chinese Journal of General Practice, 2016, 14(5): 712-714. doi: 10.16766/j.cnki.issn.1674-4152.2016.05.005
    [16]
    BAE S C, LEE Y H. Association between plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and circulating PAI-1 level in systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis[J]. Z Rheumatol, 2020, 79(3): 312-318.
    [17]
    靳岩, 张凤华, 曹盛吉, 等. 华法令和低分子肝素对狼疮抗凝物检测的干扰研究[J]. 重庆医学, 2019, 48(6): 990-992.

    JIN Y, ZHANG F H, CAO S J, et al. Study on interference of warfarin and low molecular weight heparin on lupus anticoagulant detection[J]. Chongqing Medicine, 2019, 48(6): 990-992.
    [18]
    陈梓欣, 达布西力特, 周洲, 等. 抗磷脂综合征相关心血管疾病的表现及新进展[J]. 中国循环杂志, 2024, 39(3): 306-312.

    CHEN Z X, DABXLT, ZHOU Z, et al. Research update on the phenotype of cardiovascular diseases associated with antiphospholipid syndrome[J]. Chinese Circulation Journal, 2024, 39(3): 306-312.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Article Metrics

    Article views (1) PDF downloads(0) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return